The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Vertex Pharmaceuticals Incorporated competitive analysis

Loading summary...

Latest oppositions filed by Vertex Pharmaceuticals Incorporated

Explore patent oppositions filed by Vertex Pharmaceuticals Incorporated against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4357457
Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use ThereofTOOLGEN INCORPORATEDFeb 28, 2025

Latest patents of Vertex Pharmaceuticals Incorporated opposed by its competitors

Explore Vertex Pharmaceuticals Incorporated's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3925607
Jul 16, 2025Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1
EP3880197
Jul 2, 2025Methods Of Treatment For Cystic Fibrosis2
EP4069691
Sep 18, 2024Substituted Tetrahydrofurans As Modulators Of Sodium Channels1
EP2464337
Jun 26, 2024Pharmaceutical Composition And Administrations Thereof1
EP2914248
Oct 18, 2023Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases1
EP3752510
Dec 7, 2022Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them1
EP3798214
Sep 14, 2022Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3345625
Dec 9, 2020Pharmaceutical Composition And Administrations Thereof3
EP3203840
Aug 5, 2020Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator1
EP3131582
May 23, 2018Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases1

Latest PTAB cases involving Vertex Pharmaceuticals Incorporated

Discover the latest PTAB cases involving Vertex Pharmaceuticals Incorporated, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 13, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Vertex Pharmaceuticals Incorporated

IPR2016-00558Feb 3, 2016LUPINVERTEX PHARMACEUTICALS INCORPORATEDFinal Written Decision
IPR2015-00405Dec 10, 2014LUPINVERTEX PHARMACEUTICALS INCORPORATEDTerminated-Settled
IPR2013-00024Oct 18, 2012RANBAXY LABORATORIESVERTEX PHARMACEUTICALS INCORPORATEDTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Vertex Pharmaceuticals Incorporated with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
VERTEX PHARMACEUTICALS INCORPORATED113 - 3
GENERICS UK214 - - -
LUPIN - 115 -
TEVA PHARMACEUTICALS20916 - 12